Moreover, along with an increased risk of toxicity, a phase 2 study demonstrated that pembrolizumab lacked efficacy in EGFR-mutant, PD-L1-positive, and TKI-naive patients with advanced NSCLC, including those with PD-L1 ≥50% (32). This evidence concerns the gene CD274 and non-small cell lung carcinoma.